Original language | English |
---|---|
Pages (from-to) | e283-e284 |
Journal | The Lancet Microbe |
Volume | 2 |
Issue number | 7 |
DOIs | |
State | Published - Jul 2021 |
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: The Lancet Microbe, Vol. 2, No. 7, 07.2021, p. e283-e284.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
AU - Personalized Virology Initiative study group
AU - Jangra, Sonia
AU - Ye, Chengjin
AU - Rathnasinghe, Raveen
AU - Stadlbauer, Daniel
AU - Alshammary, Hala
AU - Amoako, Angela A.
AU - Awawda, Mahmoud H.
AU - Beach, Katherine F.
AU - Bermúdez-González, Maria C.
AU - Chernet, Rachel L.
AU - Eaker, Lily Q.
AU - Ferreri, Emily D.
AU - Floda, Daniel L.
AU - Gleason, Charles R.
AU - Kleiner, Giulio
AU - Jurczyszak, Denise
AU - Matthews, Julia C.
AU - Mendez, Wanni A.
AU - Mulder, Lubbertus C.F.
AU - Russo, Kayla T.
AU - Salimbangon, Ashley Beathrese T.
AU - Saksena, Miti
AU - Shin, Amber S.
AU - Sominsky, Levy A.
AU - Srivastava, Komal
AU - Krammer, Florian
AU - Simon, Viviana
AU - Martinez-Sobrido, Luis
AU - García-Sastre, Adolfo
AU - Schotsaert, Michael
N1 - Funding Information: SJ and CY contributed equally. The Personalized Virology Initiative study group members and their affiliations, declarations of interests, and acknowledgments are listed in the appendix. This research was partly funded by the Center for Research for Influenza Pathogenesis, a Center of Excellence for Influenza Research and Surveillance supported by the National Institute of Allergy and Infectious Diseases (contract number HHSN272201400008C), by the National Cancer Institute grant U54CA260560, by the JPB Foundation and the Open Philanthropy Project (research grant 2020–215611 [5384], and by anonymous donors to AG-S. Work on SARS-CoV-2 in the Krammer and Simon laboratories was funded by the Collaborative Influenza Vaccine Innovation Centers' contract number 75N93019C00051. Research in the Martinez-Sobrido laboratory was partly funded by the New York Influenza Center of Excellence, a member of the National Institute of Allergy and Infectious Diseases, and was also partially funded by the National Institutes of Health, the Department of Health and Human Services, and the Centers of Excellence for Influenza Research and Surveillance (contract number HHSN272201400005C, New York Influenza Center of Excellence). Funding sources had no role in the study design, in the collection, analysis, and interpretation of the data, in the writing of the Correspondence, and in the decision to submit the Correspondence for publication. The García-Sastre laboratory has received research support from Pfizer, Senhwa Biosciences, and 7Hills Pharma. AG-S has consulting agreements for 7Hills Pharma, Avimex, and Esperovax involving cash, and Vivaldi Biosciences, Contrafect, Accurius, and Vaxalto involving stock. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and Newcastle disease virus-based SARS-CoV-2 vaccines which list FK as co-inventor. DS and VS are also listed on the serological assay patent application as co-inventors. FK has consulted for Merck and Pfizer (before 2020), and is currently consulting for Seqirus and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2. All other authors declare no competing interests.
PY - 2021/7
Y1 - 2021/7
UR - http://www.scopus.com/inward/record.url?scp=85104952416&partnerID=8YFLogxK
U2 - 10.1016/S2666-5247(21)00068-9
DO - 10.1016/S2666-5247(21)00068-9
M3 - Letter
AN - SCOPUS:85104952416
SN - 2666-5247
VL - 2
SP - e283-e284
JO - The Lancet Microbe
JF - The Lancet Microbe
IS - 7
ER -